2019
Short and long-term improvements in psychiatric symptomatology to validate clinically meaningful treatment outcomes for cocaine use disorders
Miguel AQC, Kiluk BD, Babuscio TA, Nich C, Mari JJ, Carroll KM. Short and long-term improvements in psychiatric symptomatology to validate clinically meaningful treatment outcomes for cocaine use disorders. Drug And Alcohol Dependence 2019, 198: 126-132. PMID: 30921648, PMCID: PMC6487863, DOI: 10.1016/j.drugalcdep.2019.01.046.Peer-Reviewed Original ResearchConceptsCocaine use disorderBrief Symptom InventoryCocaine use outcomesPsychiatric symptomatologyUse outcomesUse disordersPositive Symptom TotalDrug use outcomesMeaningful treatment outcomesInterpersonal sensitivityUse outcome measuresParanoid ideationSymptom TotalLong-term functional improvementSymptom InventoryLong-term associationPsychoticism dimensionOutcome effectsComposite scoreOutcome measuresSymptomatologyNegative urinalysis resultsGlobal indexComplete abstinenceLong-term improvement
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipants
1998
Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts
Petrakis I, Carroll K, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug And Alcohol Dependence 1998, 50: 221-226. PMID: 9649975, DOI: 10.1016/s0376-8716(98)00032-5.Peer-Reviewed Original ResearchConceptsCocaine useOpioid addictsMedication effectsDepressive symptomsSignificant decreaseEffectiveness of fluoxetineSelf-reported cocaine useDrug use outcomesSubsample of subjectsFluoxetine treatmentUrine toxicologySelf-reported useDepressive disorderSevere depressionHeroin useFluoxetineEffective agentUse outcomesDepressionPlaceboSignificant differencesTreatmentSymptomsAddictsMethadone